Clinical trial · no report yet · Phase 3
KRYSTAL-12
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
- NCT04685135 ↗
- Active not recruiting
- Mirati Therapeutics Inc.
- 137 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 96 | |
| YouTube | 22 | |
| Podcasts | 17 | |
| X videos | 2 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Metastatic Non Small Cell Lung Cancer; Advanced Non Small Cell Lung Cancer
- Interventions
- MRTX849; Docetaxel
- Arms
- MRTX849 · Experimental
- Docetaxel · Active comparator
- Enrollment
- 453
- Primary outcomes
- Progression-Free Survival (PFS) as Per Blinded Independent Central Review
- Sponsor
- Mirati Therapeutics Inc.
- Start
- Feb 23, 2021
- Primary completion
- Dec 30, 2023
- Results posted
- Yes
- Registry record
- NCT04685135 · updated Aug 11, 2026
Publications
linked from the registry- Barlesi F, Yao W, Duruisseaux M, Doucet L, Azkarate Martinez A, Gregorc V, Juan-Vidal O, Lu S, De Bondt C, de Marinis F, Linardou H, Kim YC, Jotte R, Felip E, Lo Russo G, Reck M, MichenzIe MF, Yang W, Meade JN, Korytowsky B, Mok TSK; KRYSTAL-12 Investigators. Plain language summary of the KRYSTAL-12 study results: adagrasib for non-small cell lung cancer with KRASG12C mutations. Future Oncol. 2026 Sep 16:1-12. doi: 10.1080/14796694.2026.2719409. Online ahead of print. PubMed 42745627
- Barlesi F, Yao W, Duruisseaux M, Doucet L, Martinez AA, Gregorc V, Juan-Vidal O, Lu S, De Bondt C, de Marinis F, Linardou H, Kim YC, Jotte R, Felip E, Lo Russo G, Reck M, Michenzie MF, Yang W, Meade JN, Korytowsky B, Mok TSK; KRYSTAL-12 Investigators. Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial. Lancet. 2025 Aug 9;406(10503):615-626. doi: 10.1016/S0140-6736(25)00866-9. PubMed 40783289